ICON releases its 2022 ICON Cares ESG Report
ICON announced the release of its ICON Cares 2022 Environmental, Social and Governance (ESG) Report.
ICON reports first quarter 2023 results
Revenue for the first quarter was $1,978.6 million. This represents an increase of 4.0% on prior year revenue or 5.3% on a constant currency organic basis.
ICON plc Schedules First Quarter 2023 Earnings Conference Call
ICON plc today announced that it will release its financial results for the first quarter 2023.
LEO Pharma and ICON enter a strategic partnership to propel clinical trial execution within medical dermatology
Leo Pharma Group and ICON plc today announced a strategic partnership to improve dermatology patients' lives through innovative clinical trials.
ICON plc to present at upcoming Investor Conferences
Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays Global Healthcare Conference.
ICON Reports Fourth Quarter and Full Year 2022 Results
Full year net business wins of $9,450 million; a net book to bill of 1.22.
ICON Issues Financial Guidance for Full Year 2023
ICON plc announced today its financial guidance for the year ending December 31, 2023.
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
ICON plc announced today that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
ICON finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice.